Henry SP - Search Results

1

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.

Leeds JM, Henry SP, Truong L, Zutshi A, Levin AA, Kornbrust D. Leeds JM, et al. Among authors: henry sp. Drug Metab Dispos. 1997 Aug;25(8):921-6. Drug Metab Dispos. 1997. PMID: 9280399

2

Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.

Henry SP, Grillone LR, Orr JL, Bruner RH, Kornbrust DJ. Henry SP, et al. Toxicology. 1997 Jan 15;116(1-3):77-88. doi: 10.1016/s0300-483x(96)03532-9. Toxicology. 1997. PMID: 9020509

3

An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.

Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI. Bennett CF, et al. J Pharmacol Exp Ther. 1997 Feb;280(2):988-1000. J Pharmacol Exp Ther. 1997. PMID: 9023316

4

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ. Henry SP, et al. J Pharmacol Exp Ther. 1997 May;281(2):810-6. J Pharmacol Exp Ther. 1997. PMID: 9152389

5

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

Henry SP, Bolte H, Auletta C, Kornbrust DJ. Henry SP, et al. Toxicology. 1997 Jun 27;120(2):145-55. doi: 10.1016/s0300-483x(97)03661-5. Toxicology. 1997. PMID: 9184201

6

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.

Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Geary RS, et al. Among authors: henry sp. Anticancer Drug Des. 1997 Jul;12(5):383-93. Anticancer Drug Des. 1997. PMID: 9236854 Review. No abstract available.

7

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

Henry SP, Monteith D, Levin AA. Henry SP, et al. Anticancer Drug Des. 1997 Jul;12(5):395-408. Anticancer Drug Des. 1997. PMID: 9236855 Review. No abstract available.

8

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

Henry SP, Monteith D, Bennett F, Levin AA. Henry SP, et al. Anticancer Drug Des. 1997 Jul;12(5):409-20. Anticancer Drug Des. 1997. PMID: 9236856 Review. No abstract available.

9

Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents.

Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, Crooke ST. Monteith DK, et al. Among authors: henry sp. Anticancer Drug Des. 1997 Jul;12(5):421-32. Anticancer Drug Des. 1997. PMID: 9236857

10

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.

Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ. Henry SP, et al. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):473-81. doi: 10.1089/oli.1.1997.7.473. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9361906

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters